Net Income

A powerful real estate PAC celebrates wins in the Texas primaries, but can its allies tackle the state's soaring property taxes and housing crunch?

Amid a volatile year and mounting debt, Century Casinos' upcoming Q4 results will be a critical test. Investors await news on a strategic review.

In 2025, the Northeast's largest furniture retailer supported 350+ charities, showing how its deep-rooted philanthropy is also a powerful business strategy.

Tsakos Energy Navigation reports a 200% Q4 income jump, capitalizing on high tanker rates while investing in a new fleet of LNG and VLCC vessels.

A new $175M 'cat bond' promises stability for homeowners in high-risk states, revealing the growing power of Wall Street in managing climate risk.

Award-winning supplement brand Lunakai continues its rapid 2026 expansion, bringing its popular clean-label gummy vitamins to Harvest Natural Foods.

A new drug for Raynaud's phenomenon in scleroderma patients significantly boosts attack-free days, offering hope despite missing its primary trial goal.

As pet anxiety soars, a new partnership brings a clinically proven adaptogen to the dog supplement market, setting a new standard for evidence-based care.

A recent scientific review links low glutathione to brain disease. A new supplement claims to solve the delivery problem. Is this the future of cognitive health?

Clean-tech innovator FuelPositive faces scrutiny for delaying its AGM, raising questions about governance as it races to revolutionize farming with green ammonia.

With its key earnings call on March 12, Aemetis's recent tax credit sales and project milestones are weighed against past financial performance.

Western Alliance Bank accuses Jefferies of fraud over a loan tied to the bankrupt First Brands Group, exposing a multi-billion dollar scheme.

Alpha Modus resolves its patent lawsuit against Brookshire Grocery, highlighting an aggressive IP strategy in the booming AI retail technology sector.

As cyber threats escalate, TSplus Advanced Security v7.5 delivers a multi-layered defense for Windows servers, targeting ransomware before it strikes.

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

AIRO Group will present its future vision at a major tech conference, facing investor scrutiny amid ambitious growth plans and recent financial hurdles.

Brazilian aerospace giant Embraer shatters financial records and builds its largest-ever order book, signaling a robust recovery in global aviation.

Propelled by its teen-focused Journeys brand, the footwear retailer posted strong profits, navigating mixed results in other divisions and setting a path for 2027.

With $336M in the bank and three autoimmune drugs advancing, Jade Biosciences lays out a fast-paced timeline for key clinical milestones in 2026 and 2027.

After a strategic overhaul, Aegis Brands reports a stunning Q4 profit, with its St. Louis chain's double-digit sales growth validating its new focused strategy.